Due to their broad-spectrum activity and distinct modes of action, antimicrobial peptides are considered as potential alternatives to combat the widespread adapting resistance of pathogens to conventional antibiotics. Among them, the proline-rich antimicrobial peptides (PrAMPs) family has been extensively studied as potential agents for a new generation of antibiotics1.
Previously, we showed by high resolution microscopy and flow cytometry an alteration of mechanism of antibacterial action of a designed PrAMP, Chex1-Arg20, with increasing valency from monomer to dimer and tetramer2. As well, this shift in mechanism was supported by model membrane interaction study with the PrAMP multimers. Furthermore, the effects of a series of N- and C-terminal modifications of the monomeric PrAMP, Chex1-Arg20, were studied on a panel of Gram-negative bacteria3. Use of dedicated solid phase synthesis linkers allowed peptide C-terminal modifications with hydrazide or alcohol functions which were shown to significantly extended their antibacterial activity against A. baumannii and P. aeruginosa4.
These engineered PrAMPs, modified Chex1-Arg20 and tetrameric forms, highlight the value of solid phase synthesis to advance the development of novel compounds with strong activity against nosocomial Gram-negative bacteria (E. coli, K. pneumonia, A. baumannii and P. aeruginosa).